Elizabeth Anisis, DO
Family Medicine · N Charleston, SCNPI 1851687016
Payments from drug & device makers
Across 271 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$900
- Pfizer$623
- Novo Nordisk$360
- Amgen$342
- Lilly USA, LLC$257
- AstraZeneca$251
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 67 | $900 |
| Pfizer | 37 | $623 |
| Novo Nordisk | 21 | $360 |
| Amgen | 24 | $342 |
| Lilly USA, LLC | 11 | $257 |
| AstraZeneca(2 entities) | 10 | $251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $242 |
| GSK | 11 | $205 |
| Vanda Pharmaceuticals Inc. | 14 | $194 |
| Axsome Therapeutics, Inc. | 7 | $146 |
| Astellas Pharma US Inc | 8 | $142 |
| Boston Scientific | 6 | $129 |
| Corcept Therapeutics | 4 | $96 |
| Medtronic | 5 | $91 |
| Boehringer Ingelheim | 4 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $90 |
| Sumitomo Pharma America, Inc. | 2 | $58 |
| Seqirus USA Inc | 2 | $53 |
| Exact Sciences | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Bayer | 2 | $38 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Inari Medical, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
How this compares
$4,619 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 178 | $243,394 |
| OzempicSemaglutide | 143 | $168,655 |
| JardianceEmpagliflozin | 111 | $141,522 |
| FarxigaDapagliflozin Propanediol | 111 | $131,543 |
| EliquisApixaban | 74 | $83,207 |
| JanuviaSitagliptin Phosphate | 65 | $78,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $70,639 |
| TrulicityDulaglutide | 35 | $53,698 |
| XareltoRivaroxaban | 39 | $46,428 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $35,914 |
| MyrbetriqMirabegron | 27 | $28,784 |
| EntrestoSacubitril/Valsartan | 13 | $18,938 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $17,970 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $11,397 |
| LinzessLinaclotide | 15 | $9,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $257 | $297,092213 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $251 | $176,442183 claims |
| Novo NordiskOzempic | $360 | $168,655143 claims |
| Boehringer IngelheimJardiance | $90 | $141,522111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $205 | $95,067124 claims |
| PfizerEliquis | $623 | $83,20774 claims |
| Astellas Pharma US IncMyrbetriq | $142 | $28,78427 claims |
| AbbVieLinzess, Synthroid | $900 | $11,30547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in N Charleston
- Shannon ConradN Charleston$3.3M
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.